Cerebrolysin

Grade B: Human evidence, not approved for this use

TL;DR: Cerebrolysin is a standardized injectable mixture of low-molecular-weight neuropeptides and free amino acids derived from porcine brain cortex, manufactured by EVER Pharma (Austria) and approved in approximately 45 countries for stroke and dementia indications. Multiple international randomized controlled trials have been conducted, primarily in vascular dementia and acute ischemic stroke populations, and a Cochrane-associated evidence review has assessed this body of literature; results are mixed, with some multi-center trials showing improvement in clinical outcomes and others showing uncertain or marginal benefit. Evidence quality is limited by trial heterogeneity, geographic concentration in Eastern European and Asian centers, and the biological complexity of the mixture. The Alzheimer's Drug Discovery Foundation rates the evidence as limited for healthy adults, with no trials establishing dementia prevention. As a biologically derived heterogeneous mixture, standardization across batches and manufacturers is an inherent limitation. Cerebrolysin is not FDA-approved and has no approved US indication.

Key Takeaways

Grade B: Human evidence, not approved for this use
Not FDA approved: Not FDA-approved for any indication; approved in approximately 45 countries (including Austria, Germany, Russia, China, South Korea) for stroke and dementia indications, but those approvals do not confer any US regulatory status.
Compounding: Its federal compounding status is not separately established in the FDA bulk-substance lists we verify; confirm current status with a licensed pharmacist or physician before any use.

Mechanism

Cerebrolysin is proposed to exert neuroprotective effects by delivering bioactive neuropeptide fragments that mimic endogenous neurotrophic factors (BDNF, NGF, CNTF), supporting neuronal survival, synaptic plasticity, and anti-apoptotic signaling, though the precise active components responsible have not been fully isolated.

Evidence

Cerebrolysin is a standardized injectable mixture of low-molecular-weight neuropeptides and free amino acids derived from porcine brain cortex, manufactured by EVER Pharma (Austria) and approved in approximately 45 countries for stroke and dementia indications. Multiple international randomized controlled trials have been conducted, primarily in vascular dementia and acute ischemic stroke populations, and a Cochrane-associated evidence review has assessed this body of literature; results are mixed, with some multi-center trials showing improvement in clinical outcomes and others showing uncertain or marginal benefit. Evidence quality is limited by trial heterogeneity, geographic concentration in Eastern European and Asian centers, and the biological complexity of the mixture. The Alzheimer's Drug Discovery Foundation rates the evidence as limited for healthy adults, with no trials establishing dementia prevention. As a biologically derived heterogeneous mixture, standardization across batches and manufacturers is an inherent limitation. Cerebrolysin is not FDA-approved and has no approved US indication.

Safety and risks

The animal-tissue origin of cerebrolysin introduces documented contamination risks not present with synthetic compounds: because the substance is purified from porcine brain tissue, each batch carries a speculative, undocumented prion-class risk; no prion contamination has been documented in cerebrolysin, and pigs are not natural prion hosts, though experimental susceptibility to BSE challenge has been shown. Bacterial and viral contamination risk is real and well-documented for biologics of this type, and batch composition (peptide content and concentration) varies across manufacturers. These sourcing risks are particularly relevant in the US context, where no FDA-approved manufacturing standards apply to this product. Injection itself carries inherent risks including infection, injection site reaction, and embolic events if given IV. Documented adverse effects in trials include transient headache and dizziness. Drug interaction data are sparse: the Alzheimer's Drug Discovery Foundation notes very little information on potential harmful interactions with other medications. Any cerebrolysin obtained outside a verified pharmaceutical-grade supply chain (e.g., through gray-market or unverified internet sources) carries serious additional risks from unverified porcine sourcing, sterility failures, and absence of quality testing. A 2023 Cochrane review of acute ischemic stroke found a statistically significant increase in non-fatal serious adverse events with cerebrolysin versus placebo (RR 2.39, 95% CI 1.10 to 5.23).

Interactions

Insufficient data; the ADDF specifically notes very limited information on drug interactions. Concurrent use with anticoagulants or thrombolytics in stroke settings carries theoretical additive risk but is not formally characterized.

Compounding legality

Its federal compounding status is not separately established in the FDA bulk-substance lists we verify; confirm current status with a licensed pharmacist or physician before any use.

Sources

Cerebrolysin is Not FDA approved. PeptideGrids presents evidence and regulatory status for informational purposes only. We do not sell, supply, source, or help anyone obtain this compound, and we provide no dosing or administration guidance. This is not medical advice; consult a licensed clinician. Full disclaimer.

Last reviewed June 1, 2026 by PeptideGrids editorial team (independently audited).